BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:[ U.S. CDMRP - Breast Cancer Breakthrough Award Levels 1-4 | Resea
 rch Funding ]
DTSTART;VALUE=DATE:20200312
DTSTAMP:20260427T231109Z
UID:cd8c4bfaf2103d1911a7a1132d24dea714b7aba8ce9fa337251920b3
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Breast Cancer B
 reakthrough Awards. The intent of these Awards is to support promising res
 earch that has high potential to lead to or make breakthroughs in breast c
 ancer. Scope: Research proposed under this award mechanism may be small- t
 o large-scale projects\, at different stages of idea and research developm
 ent. Four different funding levels\, based on the scope of the research\, 
 are available:\n\n	Funding Level 1: Innovative\, high-risk/high-reward res
 earch that is in the earliest stages of idea development. Research with po
 tential to yield new avenues of investigation. Proof of concept. No prelim
 inary data required.\n	Funding Level 2: Preclinical research that is alrea
 dy supported by substantial preliminary or published data and strongly val
 idates clinical translation in a well-defined context within the breast ca
 ncer landscape.\n	Funding Level 3: Advanced translational studies with a h
 igh degree of project readiness. Where relevant\, proof of availability of
  and access to necessary data\, human samples\, cohort(s) and/or critical 
 reagents must be provided. Applications must state a realistic timeline fo
 r near-term clinical investigation. Small-scale clinical trials (e.g.\, fi
 rst in human\, Phase I/Ib) may be appropriate.\n	Funding Level 4: Large-sc
 ale projects that will transform and revolutionize the clinical management
  and/or prevention of breast cancer. Human clinical trials are required.\n
 \n\nAll FY20 BCRP Breakthrough Award Levels 1 and 2 applications must addr
 ess at least one of the overarching challenges for FY20\, which are listed
  at the end of this announcement.\n\nFunding:        max. $450’000
  (Level 1)\n                        max. $1’000
 ’000 (Level 2)\n                        max. $3
 ’000’000 (Level 3)\n                        max
 . $10’000’000 (Level 4)\n\nDuration:      3 years\n\nEligibility: 
 Applicants from international organizations or institutions are eligible t
 o apply\, and there are no citizenship restrictions. Investigators at all 
 levels\, including senior postdocs\, are eligible to apply. A Mentorship S
 tatement is required for applications submitted with a PI who is a postdoc
 toral fellow.\n\nHow to Apply: Pre-applications are submitted through the 
 eBRAP platform. They should contain contact information\, a letter of inte
 nt\, and a list of collaborators and key personnel as suggested on the pla
 tform. Full applications (by invitation) will be made via a Grants.gov wor
 kspace. Full application packages can be downloaded from Grants.gov at any
  time.\n\nPre-Application Deadline\, Levels 1-2:    12-Mar-2020\, 5:00 p
 .m. EST\nPre-Application Deadline\, Levels 3-4:    13-Mar-2020\, 5:00 p.
 m. EST\n\nFull Application Deadline\, Levels 1-2:   26-Mar-2020\, 11:59 p
 .m. EST\nFull Application Deadline\, Levels 3-4:   24-Jun-2020\, 11:59 p.
 m. EST\n\nGrants.gov Funding Opportunity Numbers:   \n    W81XWH-20-
 BCRP-BTA12\n    W81XWH-20-BCRP-BTA3\n    W81XWH-20-BCRP-BTA4\n\nFu
 rther information\n\n\n	To see the program announcement\, navigate to the 
 search page on Grants.gov and search for the Opportunity Numbers W81XWH-20
 -BCRP-BTA12\, W81XWH-20-BCRP-BTA3\, or W81XWH-20-BCRP-BTA4\n	For questions
  about the eBRAP or Grants.gov platforms\, contact the Research Office.\n\
 n\nFY20 Overarching Challenges\n\n\n	Prevent breast cancer (primary preven
 tion)\n	Identify determinants of breast cancer initiation\, risk\, or susc
 eptibility\n	Distinguish deadly from non-deadly breast cancers\n	Conquer t
 he problems of overdiagnosis and overtreatment\n	Identify what drives brea
 st cancer growth\; determine how to stop it\n	Identify why some breast can
 cers become metastatic\n	Determine why/how breast cancer cells lie dormant
  for years and then re-emerge\; determine how to prevent lethal recurrence
 \n	Revolutionize treatment regimens by replacing them with ones that are m
 ore effective\, less toxic\, and impact survival\n	Eliminate the mortality
  associated with metastatic breast cancer\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR